It also inhibits tumor angiogenesis by downregulating HIF-1α and VEGF expression (27), exerting an additive anti-angiogenic effect that complements anlotinib’s inhibition of VEGF/VEGFR pathways. The gene discussed is HIF1A; the disease is neoplasm.